Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) 12-1 Month Momentum % : 44.07% (As of Apr. 29, 2024)

View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-29), Tribute Pharmaceuticals Canada's 12-1 Month Momentum % is 44.07%.

The industry rank for Tribute Pharmaceuticals Canada's 12-1 Month Momentum % or its related term are showing as below:

TBUFF's 12-1 Month Momentum % is not ranked
in the Drug Manufacturers industry.
Industry Median: -5.73 vs TBUFF: 44.07

Competitive Comparison of Tribute Pharmaceuticals Canada's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tribute Pharmaceuticals Canada's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Tribute Pharmaceuticals Canada's 12-1 Month Momentum % falls into.

Tribute Pharmaceuticals Canada (OTCPK:TBUFF) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tribute Pharmaceuticals Canada (OTCPK:TBUFF) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Tribute Pharmaceuticals Canada 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.stellarpharma.com

Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.

Executives

John M Gregory	director, 10 percent owner
Sj Strategic Investments Llc	10 percent owner
Joan P Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory	other: Member	340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines